
Volume 9, Supplement 1 (Nov/Dec 2018)
Incidence rates of melanoma continue to climb, and while most patients are diagnosed at an early stage, once metastatic, melanoma remains the most deadly of all the cutaneous malignancies. With the discovery of immune checkpoints and therapies that target the MAPK pathway, patients with metastatic melanoma have new treatment options and renewed hope.
Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes
November 27, 2018
Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma
November 27, 2018
Current Issue


The Impact of Federal Funding Cuts on Research Practice and Patient Care
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
July 14, 2025
Improving Use of Cytomegalovirus Negative and Irradiated Blood Products in an Outpatient Oncology Clinic
Susan Ezell, APRN, AGAC-NP
July 14, 2025
Supporting Administrative Time for Advanced Practitioners: A Comprehensive Approach
Meredith Beaton, RN, MSN, AGACNP, Andrea Edwards, PA-C, Wendy Vogel, MSN, FNP, AOCNP, FAPO, Et al.
July 14, 2025